A Multicenter Efficacy and Safety Study of Cluster of Differentiation 19 (CD19)-Targeted CART (CD19CART) Therapy for CD19 Positive Relapsed or Refractory B-cell Hematologic Malignancies (SCT019-01)

Trial Profile

A Multicenter Efficacy and Safety Study of Cluster of Differentiation 19 (CD19)-Targeted CART (CD19CART) Therapy for CD19 Positive Relapsed or Refractory B-cell Hematologic Malignancies (SCT019-01)

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Jun 2017

At a glance

  • Drugs Anti-CD19 CAR-transduced T cells (Primary)
  • Indications Acute lymphoblastic leukaemia; B cell lymphoma; B-cell leukaemia; Chronic lymphocytic leukaemia; Haematological malignancies; Non-Hodgkin's lymphoma
  • Focus Adverse reactions
  • Sponsors Innovative Cellular Therapeutics
  • Most Recent Events

    • 06 Jun 2017 Results assessing anti-leukemic activity of CAR-T cell therapy in pediatric patients (n=11) with relapsed/refractory acute lymphocytic leukemia, presented at the 53rd Annual Meeting of the American Society of Clinical Oncology.
    • 02 Jun 2017 Status changed to active, no longer recruiting as per results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
    • 02 Jun 2017 Results presented at the 53rd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top